Unknown

Dataset Information

0

Impact of an immune modulator fingolimod on acute ischemic stroke.


ABSTRACT: Peripheral lymphocytes entering brain ischemic regions orchestrate inflammatory responses, catalyze tissue death, and worsen clinical outcomes of acute ischemic stroke (AIS) in preclinical studies. However, it is not known whether modulating brain inflammation can impact the outcome of patients with AIS. In this open-label, evaluator-blinded, parallel-group clinical pilot trial, we recruited 22 patients matched for clinical and MRI characteristics, with anterior cerebral circulation occlusion and onset of stroke that had exceeded 4.5 h, who then received standard management alone (controls) or standard management plus fingolimod (FTY720, Gilenya, Novartis), 0.5 mg per day orally for 3 consecutive days. Compared with the 11 control patients, the 11 fingolimod recipients had lower circulating lymphocyte counts, milder neurological deficits, and better recovery of neurological functions. This difference was most profound in the first week when reduction of National Institutes of Health Stroke Scale was 4 vs. -1, respectively (P = 0.0001). Neurological rehabilitation was faster in the fingolimod-treated group. Enlargement of lesion size was more restrained between baseline and day 7 than in controls (9 vs. 27 mL, P = 0.0494). Furthermore, rT1%, an indicator of microvascular permeability, was lower in the fingolimod-treated group at 7 d (20.5 vs. 11.0; P = 0.005). No drug-related serious events occurred. We conclude that in patients with acute and anterior cerebral circulation occlusion stroke, oral fingolimod within 72 h of disease onset was safe, limited secondary tissue injury from baseline to 7 d, decreased microvascular permeability, attenuated neurological deficits, and promoted recovery.

SUBMITTER: Fu Y 

PROVIDER: S-EPMC4280578 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Impact of an immune modulator fingolimod on acute ischemic stroke.

Fu Ying Y   Zhang Ningnannan N   Ren Li L   Yan Yaping Y   Sun Na N   Li Yu-Jing YJ   Han Wei W   Xue Rong R   Liu Qiang Q   Hao Junwei J   Yu Chunshui C   Shi Fu-Dong FD  

Proceedings of the National Academy of Sciences of the United States of America 20141208 51


Peripheral lymphocytes entering brain ischemic regions orchestrate inflammatory responses, catalyze tissue death, and worsen clinical outcomes of acute ischemic stroke (AIS) in preclinical studies. However, it is not known whether modulating brain inflammation can impact the outcome of patients with AIS. In this open-label, evaluator-blinded, parallel-group clinical pilot trial, we recruited 22 patients matched for clinical and MRI characteristics, with anterior cerebral circulation occlusion an  ...[more]

Similar Datasets

| S-EPMC4580515 | biostudies-literature
| S-EPMC8011932 | biostudies-literature
| S-EPMC6282815 | biostudies-literature
| S-EPMC7540624 | biostudies-literature
| S-EPMC3250276 | biostudies-other
| S-EPMC10551008 | biostudies-literature
| S-EPMC5669343 | biostudies-literature
| S-EPMC9117458 | biostudies-literature
| S-EPMC7606819 | biostudies-literature
| S-EPMC10275827 | biostudies-literature